دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Issue Information
Empty
doi : 10.1002/acr2.11208
Volume2, Issue11,November 2020,Pages 627-628
No abstract is available for this article.
Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP)
Ann E. Clarke Arthur Weinstein Andrew Piscitello Avneet Heer Tarun Chandra Shivang Doshi John Wegener Thomas F. Goss Tami Powell
doi : 10.1002/acr2.11177
Volume2, Issue11,November 2020,Pages 629-639
Diagnosis of systemic lupus erythematosus (SLE) made by standard diagnostic laboratory tests (SDLTs) has sensitivity and specificity of 83% and 76%, respectively.
Evaluation of Improvement in Skin and Nail Psoriasis in Bio?na?ve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO?VIBRANT Study
Philip Mease M. Elaine Husni Soumya D. Chakravarty Shelly Kafka Dennis Parenti Lilianne Kim Kim Hung Lo Elizabeth C. Hsia Arthur Kavanaugh
doi : 10.1002/acr2.11180
Volume2, Issue11,November 2020,Pages 640-647
To evaluate whether intravenous (IV) golimumab produces improvements in skin and nail symptoms that are concomitant with improvements in quality of life (QoL) and joint symptoms in patients with psoriatic arthritis.
Comorbidities Before and After÷the÷Diagnosis÷of Rheumatoid Arthritis: A Matched Longitudinal Study
Mark R. Tatangelo George Tomlinson Edward Keystone J. Michael Paterson Nick Bansback Claire Bombardier
doi : 10.1002/acr2.11182
Volume2, Issue11,November 2020,Pages 648-656
To determine the contribution of rheumatoid arthritis (RA) to conditions and medical events. A secondary objective is to quantify this association before and after the introduction of biologic medications.
Expression of the Autoantigen Topoisomerase?1 is Enriched in the Lung Tissues of Patients With Autoimmune Interstitial Lung Disease: A Case Control Study
Tricia R. Cottrell Frederic Askin Marc K. Halushka Livia Casciola?Rosen Zsuzsanna H. McMahan
doi : 10.1002/acr2.11191
Volume2, Issue11,November 2020,Pages 657-661
Among the autoimmune rheumatic diseases, it is striking that autoantibodies targeting ubiquitously expressed proteins (eg, topoisomerase?1) associate with specific clinical complications (eg, interstitial lung disease [ILD]).
Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody?Associated Vasculitis
Peter A. Merkel John Niles Richard Jimenez Robert F. Spiera Brad H. Rovin Andrew Bomback Christian Pagnoux Antonia Potarca Thomas J. Schall Pirow Bekker for the CLASSIC Investigators
doi : 10.1002/acr2.11185
Volume2, Issue11,November 2020,Pages 662-671
This study aimed to evaluate the safety of avacopan, an orally administered C5a receptor inhibitor, for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis in addition to standard?of?care (SOC) treatment with glucocorticoids with cyclophosphamide or rituximab.
Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open?Label Extension of a Randomized Clinical Trial
Paul Emery Hubert van Hoogstraten Karthinathan Thangavelu Erin Mangan Gregory St John Patrick Verschueren
doi : 10.1002/acr2.11188
Volume2, Issue11,November 2020,Pages 672-680
This post hoc analysis evaluated the safety and efficacy of open?label sarilumab in patients with rheumatoid arthritis (RA) who completed the phase III double?blind ASCERTAIN study (NCT01768572) and switched from intravenous (IV) tocilizumab to subcutaneous (SC) sarilumab, or who continued SC sarilumab in the open?label extension (OLE) study EXTEND (NCT01146652).
Clinical Image: Multiple pathological fractures in a middle?aged woman: A rheumatologist?s challenge
Prashant Bafna Rasmi Ranjan Sahoo Kasturi Hazarika Kiran Preet Malhotra Anupam Wakhlu
doi : 10.1002/acr2.11193
Volume2, Issue11,November 2020,Pages 681-682
No abstract is available for this article.
Reasons for Hospitalization and In?Hospital Mortality in Adult Systemic Lupus Erythematosus
Augustine M. Manadan Soumyasri Kambhatla Estefania Gauto?Mariotti Chimuanya Okoli Joel A. Block
doi : 10.1002/acr2.11195
Volume2, Issue11,November 2020,Pages 683-689
Systemic lupus erythematosus (SLE) is an autoimmune disease with an increased risk of hospitalization. Multiple studies have reported SLE flare, infection, and cardiovascular (CV) events as the most common reasons for hospitalization. The aim of this study was to use a large US population–based database to comprehensively analyze all indications for adult SLE hospitalization and reasons for in?hospital mortality.
Erratum
Empty
doi : 10.1002/acr2.11201
Volume2, Issue11,November 2020,Pages 690-693
No abstract is available for this article.
